Jul. 17 at 5:56 AM
$PCVX Wall Street’s Bullish Outlook: Triple-Digit Upside Potential
Wall Street is overwhelmingly bullish on Vaxcyte. The company currently trades around
$33.40, but analysts see significant upside over the next 12 months. Based on the average one-year price target provided by eight analysts, Vaxcyte’s fair value sits at
$125.75, implying a potential upside of more than 276%. The high-end estimate reaches as far as
$163.00, while the low-end remains above
$65.00—still nearly double the current trading price.
